On the other hand, the lack of awareness regarding blood clotting and its severity, the high cost of diagnostic tests in some economies,Market HighlightsIt is estimated that the global Blood Coagulants Market is expected to register a CAGR ~ 11.5% with an estimated market value of USD 720.7 million during the forecast period of 2018–2023.The global market is driven by factors such as increased bleeding disorders, the rise in the research activities, and an increase in the healthcare project grants provided by public and private organizations, among others.
The growing awareness created by various non-profit organizations, as well as government campaigns help to drive the growth of the market.
For instance, the World Federation of Hemophilia (WFH) launched a Development Grant Program (DGP) in 2018 to encourage innovative ideas and projects to support the inherited bleeding disorders community globally.
The medicines were sent to countries like Vietnam, Cameroon, and others through the WFH’s Global Alliance for Progress (GAP) Program, which seeks to improve the diagnosis and treatment of bleeding disorders in developing countries.On the other hand, the lack of awareness regarding blood clotting and its severity, the high cost of diagnostic tests in some economies, and the rising counterfeit drugs are restraining the growth of blood coagulants market.
For instance, For instance, in May 2016, CSL Behring announced the US FDA approval of AFSTYLA, a recombinant factor VIII Single Chain Therapy for Hemophilia A.Request For Free Sample Copy :https://www.marketresearchfuture.com/sample_request/7632Regional AnalysisThe market in the Americas is expected to dominate the global blood coagulants market during the forecast period owing to the increasing per capita healthcare expenditure, increase in product innovation, and heavy adoption of new technology in the region.
For instance, in June 2018, Octapharma announced that the European Medicines Agency (EMA) had approved an extension of marketing authorization for its product, Nuwiq, a human cell line-derived recombinant factor VIII (rFVIII) for the treatment in patients with hemophilia A.Asia-Pacific is estimated to be the fastest growing region in the market due to the increasing number of welfare programs, coupled with the substantial generation of disposable income.